--- title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains" type: "News" locale: "en" url: "https://longbridge.com/en/news/285125143.md" description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise 2.14% to $10.52 on Monday, despite a challenging trading session for the overall market, with the NASDAQ down 0.19% and the Dow Jones down 1.13%. This marks the third consecutive day of gains for Corbus, although it remains 48.83% below its 52-week high of $20.56. In comparison, competitors like Vanda Pharmaceuticals, Fortress Biotech, and Viking Therapeutics outperformed Corbus with gains of 8.00%, 2.15%, and 5.87%, respectively. Trading volume was 282,208, surpassing the 50-day average of 246,695." datetime: "2026-05-04T21:21:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285125143.md) - [en](https://longbridge.com/en/news/285125143.md) - [zh-HK](https://longbridge.com/zh-HK/news/285125143.md) --- # Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rose 2.14% to $10.52 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 0.19% to 25,067.80 and Dow Jones Industrial Average falling 1.13% to 48,941.90. This was the stock's third consecutive day of gains. Corbus Pharmaceuticals Holdings Inc. closed 48.83% below its 52-week high of $20.56, which the company reached on October 20th. The stock underperformed when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc. (VNDA) rose 8.00% to $7.56, Fortress Biotech Inc. (FBIO) rose 2.15% to $2.38, and Viking Therapeutics Inc. (VKTX) rose 5.87% to $31.76. Trading volume (282,208) eclipsed its 50-day average volume of 246,695. Data source: Dow Jones Market Data, FactSet. Data compiled May 4, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 05-04-26 1721ET ### Related Stocks - [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md) - [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md) - [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md) - [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md) - [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md) - [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md) ## Related News & Research - [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md) - [Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs](https://longbridge.com/en/news/285622430.md) - [Canada's Knight Therapeutics Q1 revenue jumps 69%, beats estimates](https://longbridge.com/en/news/285531982.md) - [](https://longbridge.com/en/news/286273737.md) - [Pliant Therapeutics Q1 net loss narrows on lower expenses](https://longbridge.com/en/news/285998196.md)